Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells

Ragadeepthi Tunduguru, Tim T. Chiu, Latha Ramalingam, Jeffrey Elmendorf, Amira Klip, Debbie C. Thurmond

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Skeletal muscle accounts for ∼80% of postprandial glucose clearance, and skeletal muscle glucose clearance is crucial for maintaining insulin sensitivity and euglycemia. Insulin-stimulated glucose clearance/uptake entails recruitment of glucose transporter 4 (GLUT4) to the plasma membrane (PM) in a process that requires cortical F-actin remodeling; this process is dysregulated in Type 2 Diabetes. Recent studies have implicated PAK1 as a required element in GLUT4 recruitment in mouse skeletal muscle in vivo, although its underlying mechanism of action and requirement in glucose uptake remains undetermined. Toward this, we have employed the PAK1 inhibitor, IPA3, in studies using L6-GLUT4-myc muscle cells. IPA3 fully ablated insulin-stimulated GLUT4 translocation to the PM, corroborating the observation of ablated insulin-stimulated GLUT4 accumulation in the PM of skeletal muscle from PAK1-/- knockout mice. IPA3-treatment also abolished insulin-stimulated glucose uptake into skeletal myotubes. Mechanistically, live-cell imaging of myoblasts expressing the F-actin biosensor LifeAct-GFP treated with IPA3 showed blunting of the normal insulin-induced cortical actin remodeling. This blunting was underpinned by a loss of normal insulin-stimulated cofilin dephosphorylation in IPA3-treated myoblasts. These findings expand upon the existing model of actin remodeling in glucose uptake, by placing insulin-stimulated PAK1 signaling as a required upstream step to facilitate actin remodeling and subsequent cofilin dephosphorylation. Active, dephosphorylated cofilin then provides the G-actin substrate for continued F-actin remodeling to facilitate GLUT4 vesicle translocation for glucose uptake into the skeletal muscle cell.

Original languageEnglish
Pages (from-to)380-388
Number of pages9
JournalBiochemical Pharmacology
Volume92
Issue number2
DOIs
StatePublished - Nov 15 2014

Fingerprint

p21-Activated Kinases
Facilitative Glucose Transport Proteins
Muscle Cells
Muscle
Actins
Skeletal Muscle
Cells
Insulin
Glucose
Actin Depolymerizing Factors
Cell membranes
Myoblasts
Cell Membrane
Skeletal Muscle Fibers
Biosensing Techniques
Knockout Mice
Type 2 Diabetes Mellitus
Medical problems
Insulin Resistance
Biosensors

Keywords

  • Diabetes
  • F-actin remodeling
  • GLUT4 vesicle exocytosis
  • L6-GLUT4myc muscle cells
  • PAK1
  • Rac1
  • Skeletal muscle
  • Small Rho family GTPase

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry
  • Medicine(all)

Cite this

Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells. / Tunduguru, Ragadeepthi; Chiu, Tim T.; Ramalingam, Latha; Elmendorf, Jeffrey; Klip, Amira; Thurmond, Debbie C.

In: Biochemical Pharmacology, Vol. 92, No. 2, 15.11.2014, p. 380-388.

Research output: Contribution to journalArticle

Tunduguru, Ragadeepthi ; Chiu, Tim T. ; Ramalingam, Latha ; Elmendorf, Jeffrey ; Klip, Amira ; Thurmond, Debbie C. / Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells. In: Biochemical Pharmacology. 2014 ; Vol. 92, No. 2. pp. 380-388.
@article{0663d724e32f44d09d0c0ba42c6ff6cc,
title = "Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells",
abstract = "Skeletal muscle accounts for ∼80{\%} of postprandial glucose clearance, and skeletal muscle glucose clearance is crucial for maintaining insulin sensitivity and euglycemia. Insulin-stimulated glucose clearance/uptake entails recruitment of glucose transporter 4 (GLUT4) to the plasma membrane (PM) in a process that requires cortical F-actin remodeling; this process is dysregulated in Type 2 Diabetes. Recent studies have implicated PAK1 as a required element in GLUT4 recruitment in mouse skeletal muscle in vivo, although its underlying mechanism of action and requirement in glucose uptake remains undetermined. Toward this, we have employed the PAK1 inhibitor, IPA3, in studies using L6-GLUT4-myc muscle cells. IPA3 fully ablated insulin-stimulated GLUT4 translocation to the PM, corroborating the observation of ablated insulin-stimulated GLUT4 accumulation in the PM of skeletal muscle from PAK1-/- knockout mice. IPA3-treatment also abolished insulin-stimulated glucose uptake into skeletal myotubes. Mechanistically, live-cell imaging of myoblasts expressing the F-actin biosensor LifeAct-GFP treated with IPA3 showed blunting of the normal insulin-induced cortical actin remodeling. This blunting was underpinned by a loss of normal insulin-stimulated cofilin dephosphorylation in IPA3-treated myoblasts. These findings expand upon the existing model of actin remodeling in glucose uptake, by placing insulin-stimulated PAK1 signaling as a required upstream step to facilitate actin remodeling and subsequent cofilin dephosphorylation. Active, dephosphorylated cofilin then provides the G-actin substrate for continued F-actin remodeling to facilitate GLUT4 vesicle translocation for glucose uptake into the skeletal muscle cell.",
keywords = "Diabetes, F-actin remodeling, GLUT4 vesicle exocytosis, L6-GLUT4myc muscle cells, PAK1, Rac1, Skeletal muscle, Small Rho family GTPase",
author = "Ragadeepthi Tunduguru and Chiu, {Tim T.} and Latha Ramalingam and Jeffrey Elmendorf and Amira Klip and Thurmond, {Debbie C.}",
year = "2014",
month = "11",
day = "15",
doi = "10.1016/j.bcp.2014.08.033",
language = "English",
volume = "92",
pages = "380--388",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells

AU - Tunduguru, Ragadeepthi

AU - Chiu, Tim T.

AU - Ramalingam, Latha

AU - Elmendorf, Jeffrey

AU - Klip, Amira

AU - Thurmond, Debbie C.

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Skeletal muscle accounts for ∼80% of postprandial glucose clearance, and skeletal muscle glucose clearance is crucial for maintaining insulin sensitivity and euglycemia. Insulin-stimulated glucose clearance/uptake entails recruitment of glucose transporter 4 (GLUT4) to the plasma membrane (PM) in a process that requires cortical F-actin remodeling; this process is dysregulated in Type 2 Diabetes. Recent studies have implicated PAK1 as a required element in GLUT4 recruitment in mouse skeletal muscle in vivo, although its underlying mechanism of action and requirement in glucose uptake remains undetermined. Toward this, we have employed the PAK1 inhibitor, IPA3, in studies using L6-GLUT4-myc muscle cells. IPA3 fully ablated insulin-stimulated GLUT4 translocation to the PM, corroborating the observation of ablated insulin-stimulated GLUT4 accumulation in the PM of skeletal muscle from PAK1-/- knockout mice. IPA3-treatment also abolished insulin-stimulated glucose uptake into skeletal myotubes. Mechanistically, live-cell imaging of myoblasts expressing the F-actin biosensor LifeAct-GFP treated with IPA3 showed blunting of the normal insulin-induced cortical actin remodeling. This blunting was underpinned by a loss of normal insulin-stimulated cofilin dephosphorylation in IPA3-treated myoblasts. These findings expand upon the existing model of actin remodeling in glucose uptake, by placing insulin-stimulated PAK1 signaling as a required upstream step to facilitate actin remodeling and subsequent cofilin dephosphorylation. Active, dephosphorylated cofilin then provides the G-actin substrate for continued F-actin remodeling to facilitate GLUT4 vesicle translocation for glucose uptake into the skeletal muscle cell.

AB - Skeletal muscle accounts for ∼80% of postprandial glucose clearance, and skeletal muscle glucose clearance is crucial for maintaining insulin sensitivity and euglycemia. Insulin-stimulated glucose clearance/uptake entails recruitment of glucose transporter 4 (GLUT4) to the plasma membrane (PM) in a process that requires cortical F-actin remodeling; this process is dysregulated in Type 2 Diabetes. Recent studies have implicated PAK1 as a required element in GLUT4 recruitment in mouse skeletal muscle in vivo, although its underlying mechanism of action and requirement in glucose uptake remains undetermined. Toward this, we have employed the PAK1 inhibitor, IPA3, in studies using L6-GLUT4-myc muscle cells. IPA3 fully ablated insulin-stimulated GLUT4 translocation to the PM, corroborating the observation of ablated insulin-stimulated GLUT4 accumulation in the PM of skeletal muscle from PAK1-/- knockout mice. IPA3-treatment also abolished insulin-stimulated glucose uptake into skeletal myotubes. Mechanistically, live-cell imaging of myoblasts expressing the F-actin biosensor LifeAct-GFP treated with IPA3 showed blunting of the normal insulin-induced cortical actin remodeling. This blunting was underpinned by a loss of normal insulin-stimulated cofilin dephosphorylation in IPA3-treated myoblasts. These findings expand upon the existing model of actin remodeling in glucose uptake, by placing insulin-stimulated PAK1 signaling as a required upstream step to facilitate actin remodeling and subsequent cofilin dephosphorylation. Active, dephosphorylated cofilin then provides the G-actin substrate for continued F-actin remodeling to facilitate GLUT4 vesicle translocation for glucose uptake into the skeletal muscle cell.

KW - Diabetes

KW - F-actin remodeling

KW - GLUT4 vesicle exocytosis

KW - L6-GLUT4myc muscle cells

KW - PAK1

KW - Rac1

KW - Skeletal muscle

KW - Small Rho family GTPase

UR - http://www.scopus.com/inward/record.url?scp=84908324599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908324599&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2014.08.033

DO - 10.1016/j.bcp.2014.08.033

M3 - Article

VL - 92

SP - 380

EP - 388

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 2

ER -